MX2022006655A - Uso de nucleosomas libres de celulas como biomarcadores. - Google Patents

Uso de nucleosomas libres de celulas como biomarcadores.

Info

Publication number
MX2022006655A
MX2022006655A MX2022006655A MX2022006655A MX2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A MX 2022006655 A MX2022006655 A MX 2022006655A
Authority
MX
Mexico
Prior art keywords
biomarkers
cell free
free nucleosomes
nucleosomes
vascular
Prior art date
Application number
MX2022006655A
Other languages
English (en)
Spanish (es)
Inventor
Mark Edward Eccleston
Jacob Vincent Micallef
Heather Wilson-Robles
Marielle Chantal Andree Herzog
Jason Bradley Terrell
Original Assignee
Belgian Volition Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition Srl filed Critical Belgian Volition Srl
Publication of MX2022006655A publication Critical patent/MX2022006655A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022006655A 2019-12-02 2020-12-02 Uso de nucleosomas libres de celulas como biomarcadores. MX2022006655A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US202063088408P 2020-10-06 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Publications (1)

Publication Number Publication Date
MX2022006655A true MX2022006655A (es) 2022-09-07

Family

ID=73698838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006655A MX2022006655A (es) 2019-12-02 2020-12-02 Uso de nucleosomas libres de celulas como biomarcadores.

Country Status (15)

Country Link
US (1) US20230003735A1 (enExample)
EP (2) EP4435431A3 (enExample)
JP (2) JP7693670B2 (enExample)
KR (1) KR102930652B1 (enExample)
CN (1) CN114829939B (enExample)
AU (1) AU2020395504A1 (enExample)
BR (1) BR112022010774A2 (enExample)
CA (1) CA3163181A1 (enExample)
ES (1) ES2988371T3 (enExample)
IL (1) IL293342B2 (enExample)
MX (1) MX2022006655A (enExample)
PL (1) PL4070111T3 (enExample)
TW (1) TWI902730B (enExample)
WO (1) WO2021110776A1 (enExample)
ZA (1) ZA202205916B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2015138774A1 (en) 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
US20250197944A1 (en) 2022-03-11 2025-06-19 Belgian Volition Srl Differential diagnosis method
EP4577833A1 (en) 2022-08-25 2025-07-02 Belgian Volition SRL Method for measuring cell free chromatin
EP4639173A1 (en) * 2022-12-19 2025-10-29 Belgian Volition SRL Calibration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB0413732D0 (en) * 2004-06-13 2004-07-21 Chroma Therapeutics Ltd Histone modification
ATE534908T1 (de) * 2009-08-03 2011-12-15 Universitaetsklinikum Freiburg Verfahren und verbindungen zur diagnose und behandlung von krebs
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
JP6263474B2 (ja) 2011-12-07 2018-01-17 シンガポール ボリション ピーティーイー リミテッド ヌクレオソームアダクト検出法
EP4155401A1 (en) * 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
SG11201702978VA (en) 2014-10-29 2017-05-30 Belgian Volition Sprl Method for the enrichment of circulating tumor dna
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
CN111918971B (zh) * 2018-03-01 2024-09-03 埃皮塞弗公司 利用化学确定的重组核小体定量核小体修饰

Also Published As

Publication number Publication date
CA3163181A1 (en) 2021-06-10
JP7693670B2 (ja) 2025-06-17
JP2023503379A (ja) 2023-01-27
IL293342B2 (en) 2026-05-01
EP4435431A2 (en) 2024-09-25
EP4070111B1 (en) 2024-08-21
BR112022010774A2 (pt) 2022-08-23
TW202134654A (zh) 2021-09-16
IL293342B1 (en) 2026-01-01
ES2988371T3 (es) 2024-11-20
EP4070111C0 (en) 2024-08-21
CN114829939A (zh) 2022-07-29
AU2020395504A1 (en) 2022-06-23
PL4070111T3 (pl) 2025-02-03
ZA202205916B (en) 2024-09-25
KR102930652B1 (ko) 2026-02-25
EP4070111A1 (en) 2022-10-12
WO2021110776A1 (en) 2021-06-10
US20230003735A1 (en) 2023-01-05
KR20220110794A (ko) 2022-08-09
CN114829939B (zh) 2025-10-21
TWI902730B (zh) 2025-11-01
EP4435431A3 (en) 2024-10-16
JP2025124845A (ja) 2025-08-26
IL293342A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
ZA202205916B (en) Use of cell free nucleosomes as biomarkers
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
EP4458849A3 (en) Biomarkers for pancreatic cancer
GB2511221A (en) Methods and compositions for classification of samples
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
EP3816303A3 (en) Breast cancer detection kit or device, and method for detecting breast cancer
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
MX2017009768A (es) Ligadores lábiles para detección de biomarcadores.
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
MX2018013223A (es) Reacción de cadena de polimerasas para amplificación de discordancias optimizada multiplicada (moma)-en tiempo real para la valoración de cáncer.
HK1246828A1 (zh) 用於检测癌症的生物标志物组
EP4461824A3 (en) Detection kit or device and detection method for biliary tract cancer
EP3862439A3 (en) Liver cancer detection kit or device, and detection method
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
EP2673631A1 (en) Methods and systems for determining the presence or amount of testosterone in a sample
EP3201812A4 (en) Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
AU2018262331A8 (en) Methods for trapping and barcoding discrete biological units in hydrogel
EP4614153A3 (en) Cancer biomarkers
MX2021000899A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
MX2017011198A (es) Biomarcadores para preeclampsia.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2016016507A (es) Composiciones y metodos para tratar canceres.